Namritha V Patrao1, Sheelah Antao1, Catherine Egan1, Amer Omar1, Robin Hamilton2, Philip G Hykin1, Sobha Sivaprasad2, Ranjan Rajendram3. 1. National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom. 2. National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom; University College of London Institute of Ophthalmology, London, United Kingdom. 3. National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom; University College of London Institute of Ophthalmology, London, United Kingdom. Electronic address: ranjan.rajendram@ucl.ac.uk.
Abstract
PURPOSE: To determine visual acuity (VA) and spectral-domain optical coherence tomography (OCT) outcomes with intravitreal ranibizumab for diabetic macular edema (DME) in a United Kingdom National Health Service clinical setting. DESIGN: Retrospective interventional case series. PARTICIPANTS: Consecutive patients with DME, treated with the first ranibizumab injection between August 2013 and March 2014 across 4 sites of Moorfields Eye Hospital, London. METHODS: Two hundred eyes of 164 consecutive patients with center-involving DME and VA ≤79 ETDRS letters, central subfield macular thickness (CST) ≥350 μm on Topcon 3D OCT 2000, initiated on a loading phase of 3 intravitreal ranibizumab injections and who had at least 6 months follow-up were reviewed. Subsequent retreatment was guided by VA and OCT with the aim of treating to stability. VA, OCT CST, and macular volume (MV) were recorded at baseline and monthly to 12 months. RESULTS: The mean VA, mean CST, and mean MV at baseline were 54.4 (± 15.26) letters, 490.16 (± 116.54) μm, and 10.46 (± 2.28) mm3. The mean VA change at 12 months was +6.6 (± 13.35) letters (P = .0003). A total of 40.3% of patients (n = 77) gained ≥10 letters and 25.1% (n = 48) gained ≥15 letters; 8.9% (n = 17) lost ≥10 letters and 6.3% (n = 12) lost ≥15 letters. At 12 months, the mean change in CST and MV were -133.9 (± 160.12) μm (P = .0001) and -1.5 (± 1.96) mm3 (P = .0001), respectively. An average of 7.2 (± 2.3) injections were given over 12 months. CONCLUSIONS: Outcomes with 3 loading injections of 0.5 mg ranibizumab given monthly followed by pro re nata retreatment in a clinical setting are comparable with outcomes from clinical trials.
PURPOSE: To determine visual acuity (VA) and spectral-domain optical coherence tomography (OCT) outcomes with intravitreal ranibizumab for diabetic macular edema (DME) in a United Kingdom National Health Service clinical setting. DESIGN: Retrospective interventional case series. PARTICIPANTS: Consecutive patients with DME, treated with the first ranibizumab injection between August 2013 and March 2014 across 4 sites of Moorfields Eye Hospital, London. METHODS: Two hundred eyes of 164 consecutive patients with center-involving DME and VA ≤79 ETDRS letters, central subfield macular thickness (CST) ≥350 μm on Topcon 3D OCT 2000, initiated on a loading phase of 3 intravitreal ranibizumab injections and who had at least 6 months follow-up were reviewed. Subsequent retreatment was guided by VA and OCT with the aim of treating to stability. VA, OCT CST, and macular volume (MV) were recorded at baseline and monthly to 12 months. RESULTS: The mean VA, mean CST, and mean MV at baseline were 54.4 (± 15.26) letters, 490.16 (± 116.54) μm, and 10.46 (± 2.28) mm3. The mean VA change at 12 months was +6.6 (± 13.35) letters (P = .0003). A total of 40.3% of patients (n = 77) gained ≥10 letters and 25.1% (n = 48) gained ≥15 letters; 8.9% (n = 17) lost ≥10 letters and 6.3% (n = 12) lost ≥15 letters. At 12 months, the mean change in CST and MV were -133.9 (± 160.12) μm (P = .0001) and -1.5 (± 1.96) mm3 (P = .0001), respectively. An average of 7.2 (± 2.3) injections were given over 12 months. CONCLUSIONS: Outcomes with 3 loading injections of 0.5 mg ranibizumab given monthly followed by pro re nata retreatment in a clinical setting are comparable with outcomes from clinical trials.
Authors: Paul Mitchell; Tom G Sheidow; Michel E Farah; Sajjad Mahmood; Angelo M Minnella; Nicole Eter; Bora Eldem; Hassan Al-Dhibi; Wayne Macfadden; Soumil Parikh; Cornelia Dunger-Baldauf; Mohamed M Mahgoub; Ursula Schmidt-Erfurth Journal: PLoS One Date: 2020-06-03 Impact factor: 3.240
Authors: Fangyao Tang; Xi Wang; An-Ran Ran; Carmen K M Chan; Mary Ho; Wilson Yip; Alvin L Young; Jerry Lok; Simon Szeto; Jason Chan; Fanny Yip; Raymond Wong; Ziqi Tang; Dawei Yang; Danny S Ng; Li Jia Chen; Marten Brelén; Victor Chu; Kenneth Li; Tracy H T Lai; Gavin S Tan; Daniel S W Ting; Haifan Huang; Haoyu Chen; Jacey Hongjie Ma; Shibo Tang; Theodore Leng; Schahrouz Kakavand; Suria S Mannil; Robert T Chang; Gerald Liew; Bamini Gopinath; Timothy Y Y Lai; Chi Pui Pang; Peter H Scanlon; Tien Yin Wong; Clement C Tham; Hao Chen; Pheng-Ann Heng; Carol Y Cheung Journal: Diabetes Care Date: 2021-07-27 Impact factor: 17.152